
|Videos|July 7, 2023
The AMPECT Trial: Nab-sirolimus in PEComa
Dr Andrew Wagner shares data from the AMPECT trial investigating the potential role of mTOR inhibitors in PEComa.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 ASCO Plenary Delivers Practice-Changing Progress
2
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
3
FDA Clears US Enrollment for Ateganosine Phase 2 NSCLC Trial Expansion
4
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
5






































